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ABSTRACT 
 
Background: Atrial fibrillation (AF) is associated with an increased risk of stroke, and the use 
of oral anticoagulation reduces stroke and all-cause mortality. Geographical differences may 
exist in AF risk factors, risk stratification and treatment strategies.  
Methods: A post-hoc subgroup analysis derived from randomized controlled trials, the 
SPORTIF III and V trials, studying differences between European and North American 
warfarin-assigned non-valvular AF patients. 
Results: Of 3359 patients 41.6% (n=1397) were enrolled in Europe and 1962 (58.4%) from 
North America. CHA2DS2-VASc (p=0.002) and HAS-BLED (p<0.001) scores were higher in 
North Americans. Good anticoagulation control was more common in North American 
patients than Europeans. 
1-Kaplan-Meier estimate curves show that North Americans had a lower risk of 
stroke/systemic embolic event (SEE) (p=0.012), but higher risk of myocardial infarction(MI) 
(p=0.007) and major bleeding (p<0.001), compared to Europeans. Cox multivariate analysis 
confirmed a lower stroke/SEE risk (p=0.008) and higher MI (p=0.014) and major bleeding 
risks(p<0.001) in North Americans.  
Conclusions: Compared to European AF patients, North Americans had better 
anticoagulation control and higher thromboembolic and bleeding risk profiles. At follow-up, 
North American patients had lower stroke/SEE risk but higher MI and major bleeding risks 
compared to Europeans. Further studies are needed to understand these differences and 
the discordance between risk profile and lower stroke/SEE rates in North American 
compared to European patients. 
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1. INTRODUCTION 
 
Atrial fibrillation (AF) epidemiology is constantly changing, and both prevalence and 
incidence of AF are increasing with projected data showing that in 2020 up to 8.8 million 
and in 2060, 17.9 million European adult subjects will be diagnosed with AF[1]. 
 
The Framingham Heart Study has provided important insights into AF risk factors, clinical 
characteristics and outcomes[2–4].  More recently published evaluations of the impact of AF 
on global disease burden show that differences between USA and Europe clearly exist in 
terms of prevalence, clinical management, anticoagulation use and outcomes 
occurrence[5,6]. Other observational data, such as the Global Registry on Long-Term Oral 
Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry has 
providing insights into actual differences in management of antithrombotic therapy in the 
new era of the non-vitamin K antagonist oral anticoagulants (NOACs)[7]. 
 
The aims of this analysis were to describe geographical differences between Europe and 
North America in terms of clinical characteristics and major adverse outcomes from a large 
cohort of patients with non-valvular AF anticoagulated with warfarin in a randomized 
controlled trial (RCT) cohort with adjudicated outcome events. 
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2. METHODS 
 
For the purposes of the present study, we analysed the pooled dataset from the Stroke 
Prevention using an Oral Thrombin Inhibitor in patients with atrial Fibrillation (SPORTIF) III 
and V trials. Details on the trial protocol have been reported elsewhere[8]. 
Outcomes assessment was performed blinded from a central adjudication committee for 
both the studies.  
Anticoagulation control, as reflected by time in therapeutic range (TTR) was calculated 
according to the standardized Rosendaal interpolation method[9]. 
Thromboembolic risk was categorised according to CHA2DS2-VASc score[10]. Bleeding risk 
was evaluated according to the HAS-BLED risk score[11]. 
Details about study design, TTR calculation, risk stratification and outcomes definition have 
been reported in the Supplementary Materials (Supplementary Methods). 
 
2.1 Statistical Analysis 
All continuous variables were tested for normality. Variables with normal distribution were 
expressed as means and standard deviations (SD). Non-normal distributed variables were 
expressed as median and interquartile range (IQR). Categorical variables, expressed as 
counts and percentages, were analysed by chi-squared test. Comparison between 
distributions of TTR in the two regions was assessed with Kolmogorov-Smirnov (K-S) test. 
 
A linear regression analysis to explore clinical factors significantly associated with TTR 
according to geographical location was performed. Based on the univariate analysis, all 
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variables with a p-value <0.10 for the association were entered into the multivariate 
analysis. 
 
Survival analysis, assessed by an intention-to-treat approach, was performed according 
geographical location; differences in cumulative risk were analysed using the log-rank test 
and 1-Kaplan-Meier curves estimates were drafted according to the different groups. 
Evaluation of clinical characteristics significantly associated with outcomes was explored 
using a Cox proportional-hazards analysis. All variables considered at baseline were 
considered for the univariate analyses. All variables with a p-value <0.10 for the association 
in the univariate analysis, were included into the stepwise multivariate model. Specific Cox 
models according to both Europe and North America were also performed. A two-sided p 
value <0.05 was considered statistically significant. All analyses were performed using SPSS 
v. 22.0 (IBM, NY, USA).
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3. RESULTS 
 
Of the 3665 patients originally assigned to the warfarin arm, 3359 (91.6%) of these were 
randomized either in Europe or North America: 1397 (41.6%) in Europe and 1962 (58.4%) in 
North America. At baseline (Table 1), patients enrolled in North America were older 
(p<0.001), had a higher BMI (p<0.001), with more prevalent paroxysmal AF (p<0.001) 
compared to those enrolled in Europe. Proportion of patients with a creatinine clearance 
(CrCL) <60 ml/min was higher in North American than in European patients (p=0.042). 
 
North America patients had more prior hypertension (p<0.001) but good blood pressure 
control (<140/90 mmHg) was more commonly achieved in North America, when compared 
to Europeans (p<0.001). Concomitant diabetes mellitus (p=0.038), coronary artery disease 
[CAD] (p<0.001) and chronic heart failure [CHF] (p=0.005) were more prevalent in North 
American patients, as was a previous bleeding episode (p<0.001).  Conversely, a history of 
stroke/transient ischemic attack [TIA] was less common in North American patients than 
Europeans (p=0.014). Prior vitamin K antagonist (VKA) use was more common in North 
American patients than in Europe (<0.001). 
 
Median CHA2DS2-VASc score was higher amongst North American patients (p=0.002), with a 
trend for more high thromboembolic risk patients (CHA2DS2-VASc score ≥2) being enrolled 
in North America compared to Europe (p=0.059).  Bleeding risk was higher in North 
American compared to European patients, both in terms of HAS-BLED score distribution 
(p<0.001) and the proportion with a high bleeding risk profile (p=0.012). 
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3.1 Time in Therapeutic Range (TTR) 
As shown in Table 1, median TTR values were similar between Europe and North America 
(p=0.893), but the distribution of TTR values was different among the two geographical 
regions (Figure 1).  In North America, the distribution of TTR tended towards higher values 
when compared to Europeans (K-S test: 1.597, p=0.012). 
 
While no difference was found in the proportion of patients achieving optimal 
anticoagulation control (TTR>70%) (p=0.893), the proportion of patients with poor INR 
control was lower in North American patients than in Europeans (Table 1), with significant 
differences being evident for the proportions with TRR<60% and TTR<50% (p=0.003 and 
p=0.007, respectively). 
 
A regression analysis of the clinical predictors of TTR showed differences between the two 
geographical regions [Table 2].  In North American patients, female sex (p=0.001), 
concomitant diabetes mellitus (p=0.015) and CHF (p=0.003) were inversely associated with 
increasing TTR, while persistent AF (p=0.001) and prior VKA use (p<0.001) were positively 
associated with increasing TTR.  In European patients, TTR was associated with hypertension 
(p=0.012), particularly with progressively increasing diastolic blood pressures at baseline 
(p<0.001), and prior VKA use (p<0.001).  
 
3.2 Follow-Up and Survival 
After a median [IQR] follow-up of 576 [500-657] days, there were 81 (2.4%) stroke/SEE 
events, 49 (1.5%) MI, 118 (3.5%) major bleeds, 192 (5.7%) all-cause deaths and 256 (7.6%) 
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composite outcome events. Only 7 (0.2%) patients reported haemorrhagic stroke, so no 
subgroup analysis was performed given the small numbers.  
 
Based on geographical location (Supplementary Table 1), a higher rate of stroke/SEE was 
found for European patients compared to those enrolled in North America (3.1% vs. 1.9%, 
respectively; p=0.019). Conversely, both myocardial infarction and major bleeding rates 
were higher in North American patients compared to Europeans (1.9% vs. 0.8%, p=0.006 
and 4.5% vs. 2.1%, p<0.001 respectively). No geographical differences were found in rates of 
all-cause death and the composite outcome. Similar results were found when considering 
annualized incidence rates (Supplementary Table 1). 
 
1-Kaplan-Meier estimate curves (Supplementary Figure 1) show that European patients had 
a higher risk for stroke/SEE (Log-Rank: 6.254, p=0.012), while North American patients had a 
higher risk for MI (Log-Rank: 7.383, p=0.007) and major bleeding (Log-Rank: 13.029, 
p<0.001).  
 
3.3 Multivariable Analyses 
A Cox regression analyses, according to geographic location, was performed (Supplementary 
Table 2).  In Europe, previous stroke/TIA (p=0.014) and CAD (p<0.001) were independently 
associated with the occurrence of Stroke/SEE, while TTR (p=0.013) was inversely associated 
with this endpoint.  In North America, only the TTR (p=0.012) was inversely associated with 
Stroke/SEE.  
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 10 
When investigating risk factors associated with MI in Europe, age (p=0.004) was only 
significant risk factor, while in North Americans, both previous stroke/TIA (p=0.003) and 
established CAD (p=0.001) were associated with an increased risk for MI, whilst the use of 
aspirin was inversely associated with MI (p=0.013).  
 
Age was independently associated with major bleeding both for Europe and North America 
(p=0.045 and p=0.001, respectively) whilst TTR was inversely associated with this endpoint 
in both geographical regions (p=0.004 and p<0.001, respectively).  Female sex was inversely 
associated with major bleeding (p=0.019) in Europe whilst diabetes mellitus (p=0.0036) was 
also associated with major bleeding in North America. 
 
In the overall cohort, a Cox regression analysis (Table 3) confirmed that European patients 
had a higher risk for Stroke/SEE (p=0.008) compared to North American patients, 
independent of other concomitant risk factors.  In contrast, North American patients had a 
higher risk for both MI (p=0.014) and major bleeding (p<0.001), independent of other 
concomitant risk factors. 
 
3.4 Sensitivity Analysis 
A sensitivity analysis was performed using CrCl<60 ml/min as a categorical variable in the 
Cox regression analysis model (Supplementary Table 3). On univariate analysis CrCl<60 
ml/min was associated with both stroke/SEE (hazard ratio [HR]: 2.01, 95% confidence 
interval [CI]: 1.28-3.15, p=0.002) and major bleeding (HR: 1.57, 95% CI: 1.07-2.32, p=0.021).  
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After multivariable regression analysis, CrCl<60 ml/min was independently associated with 
stroke/SEE o (p=0.007), confirming previous analysis coming from this same dataset[12]. 
European patients had a higher risk of stroke (p=0.009) compared to North Americans, while 
North American patients had a higher risk for major bleeding (p<0.001), independently of a 
CrCl<60 ml/min. 
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4. DISCUSSION 
 
In this ancillary analysis from the SPORTIF trials, several differences in risk factors are 
evident between Europe and in North America amongst non-valvular AF patients.  
Specifically, North American patients had more comorbidities with associated higher 
thromboembolic and bleeding risk profiles. North American patients reported a better 
anticoagulation control management (as reflected by TTR), when compared to Europeans. 
Despite geographical differences in comorbidities and TTRs, European patients had a higher 
risk for Stroke/SEE compared to North American patients, whilst the latter had a higher risk 
for both MI and major bleeding, even after adjusting for confounders on multivariate 
analysis. These differential risks appear to be independent from a reduced renal function 
(CrCl<60 ml/min), which is a powerful predictor of both thromboembolic and bleeding 
risks[12]. 
 
Chugh and colleagues have clearly shown how the prevalence of AF in North America has 
been higher than in Europe over the last 20 years[5]. Despite this, the proportion of deaths 
attributable to AF has been higher in Europe than in North America, even if North American 
AF patients had a higher proportion of disability-adjusted life-years (DALYs) compared to 
Europeans[5]. Rahman et al. have also shown how CAD and CHF are more prevalent 
concomitant comorbidities in USA than in Europe, compared to either hypertension or 
diabetes mellitus[6].  In this study, we also confirm the higher prevalence of CAD and CHF in 
North American AF patients. 
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Prior studies AF patients in USA have previously reported lower TTR values, ranging from 
29%[13] to 62%[14], although anticoagulation clinic based studies have reported slightly 
higher TTR values (68%)[15]. Conversely, studies from European countries have always 
showed higher mean TTRs, ranging from 56%[16] to 75%[17].  One observational study, the 
international study of anticoagulation management (ISAM), clearly showed that patients 
enrolled in North America had lower TTR values than those enrolled in Europe[18]. A large 
meta-analysis including data from 69 studies exploring TTR and outcomes in AF patients[19], 
reported that European patients had mean TTR values that were on average 9.7% (95% CI: 
6.0-13.4%) higher than North Americans (p<0.001). Interestingly, our data show the 
converse, that North American patients had a greater proportion of good TTR, in particular 
TTR>60% and TTR>50%, indicating that within a setting with regular review and follow-up 
(as in clinical trials), North American AF patients could achieve a good TTR.  In contrast, data 
coming from a subgroup analyses of the Rivaroxaban Once Daily Oral Direct Factor Xa 
Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial 
in Atrial Fibrillation (ROCKET AF) trial reported no differences in TTR values between North 
America and Europe[20]. 
 
In North American patients, various comorbidities and demographic characteristic were 
associated with a better TTR while in European patients, hypertension was the main factor 
associated with TTR.  Our observation that diabetes mellitus and CHF were the main clinical 
factors inversely associated with TTR, is consistent with an ancillary study coming from the 
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry, 
where both comorbidities were associated with a poor TTR[21].  Various clinical 
comorbidities are known to influence TTR, as incorporated into the SAMe-TT2R2 score, 
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which is to aid decision making as to the likelihood of achieving a good TTR (score 0-2) or 
not (score >2)[22,23]. Of note, determinants of TTR varied between North America and 
Europe. 
Conversely, VKA experienced patients in both regions were more likely to have better 
anticoagulation control, consistent with previously reported data[19,20]. 
 
The evidence of a poorer TTR among European patients could explain why North American 
patients had a lower risk for Stroke/SEE occurrence, despite having a higher 
thromboembolic risk profile. The concept that residual risk for adverse outcomes in AF 
patients is closely related to TTR is strongly supported by current literature, with an inverse 
relationship between increasing TTR and adverse outcomes[24–26]. Gallagher et al. 
demonstrated that the proportion of patients free from stroke was proportionally lower 
with worse TTR[27].  Since North American patients had more comorbidities, physicians may 
be more likely to monitor and review them more intensively.  
 
Our multivariable analyses suggest that European patients have a higher excess of risk due 
to previous cerebrovascular and cardiovascular disease, whilst North American patients may 
have had better management of comorbidities, as well as better TTR. Of note, TTR was 
consistently important, being inversely related to bleeding risk irrespective of geographical 
region. Despite the higher comorbidities in North America, adverse outcomes differed, with 
European patients having a higher risk for Stroke/SEE whilst North American patients had a 
higher risk for both MI and major bleeding.  These differential expressions of adverse 
outcomes merit further study. 
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4.1 Limitations 
The major limitation to this paper is clearly its post-hoc ancillary nature, as well as the study 
design that enrolled separately in North America and Europe patients for the SPORTIF V and 
SPORTIF III trials, respectively.  Trial designs were also different where SPORTIF V was a 
double-blind double dummy trial, whilst SPORTIF III was open-label, even if both inclusion 
and exclusion criteria were exactly the same in both studies. Since the presented subgroups 
were not pre-specified, our results could be based on a limited power and partially limit 
their generalizability.  Our hypothesis focuses on geographical differences rather than ethnic 
differences, which would require a separate analysis given the many different ethnicities in 
North America and Europe.  Also, data about concomitant medications such as statins and 
others, that could interact with mortality risk, were not available for this analysis. 
Furthermore, no other measures of anticoagulation control were available, in order to verify 
our findings. Finally, the trial data and population reflected practice nearly ten years ago, 
and may not precisely reflect current epidemiology and clinical practice.  Nonetheless, our 
data have to be considered hypothesis-generating. Differences that we underlined should 
be taken into consideration for future studies, also focusing on ethnic differences whenever 
possible, to assess if real differences exist in terms of excess risk among European and North 
American populations. 
 
5. CONCLUSIONS 
North American AF patients, when compared to European ones, had better anticoagulation 
control, higher thromboembolic and bleeding risk profiles. At follow-up, North American 
patients had lower stroke/SEE rates but higher myocardial infarction and major bleeding 
rates compared to Europeans.  Further studies are needed to understand the geographical 
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differences in high event rates amongst AF patients, and the discord between high risk 
profile and lower stroke/thromboembolism rates in North American compared to European 
patients with AF. 
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Table 1: Baseline characteristics according to geographic region 
 Europe 
N= 1397 
North America 
N= 1962 
p 
Age years, median [IQR] 71 [66-76] 73 [66-78] <0.001 
Female Sex, n (%) 436 (31.2) 609 (31.0) 0.916 
BMI kg/m2, median [IQR] 3345 28.1 [25.2-31.1] 28.5 [25.4-32.9] <0.001 
CrCl ml/min, median [IQR] 3342 81.1 [61.6-103.5] 79.3 [59.2-103.9] 0.219 
CrCl<60 ml/min, n (%) 317 (22.9) 507 (25.9) 0.042 
Blood Pressure <140/90 mmHg, n (%) 531 (38.1) 1160 (59.3) <0.001 
Type of AF, n (%) 
Paroxysmal AF 
Persistent AF 
 
108 (7.7) 
1289 (92.3) 
 
270 (13.8) 
1690 (86.2) 
<0.001 
Hypertension, n (%) 1014 (72.6) 1582 (80.6) <0.001 
Diabetes Mellitus, n (%) 301 (21.5) 483 (24.6) 0.038 
Current Smoking, n (%) 132 (9.4) 165 (8.4) 0.296 
Coronary Artery Disease, n (%) 560 (40.1) 944 (48.1) <0.001 
Previous Stroke/TIA, n (%) 295 (21.1) 348 (17.7) 0.014 
Chronic Heart Failure, n (%) 494 (35.4) 788 (40.2) 0.005 
Previous Bleeding, n (%) 55 (3.9) 140 (7.1) <0.001 
Concomitant Aspirin Use, n (%) 281 (20.1) 367 (18.7) 0.308 
Prior VKA Use, n (%) 993 (71.1) 1667 (84.7) <0.001 
CHA2DS2-VASc, median [IQR] 3 [2-4] 3 [2-4] 0.002 
Thromboembolic Risk, n (%)   0.059 
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Low 
Medium 
High 
2 (0.1) 
203 (14.5) 
1192 (85.3) 
4 (0.2) 
231 (11.8) 
1727 (88.0) 
HAS-BLED, median [IQR] 3302 
0-2, n (%) 
≥3, n (%) 
3 [2-4]  
433 (31.4) 
947 (68.6) 
3 [2-4] 
526 (27.4) 
1396 (72.6) 
<0.001 
0.012 
Time in Therapeutic Range 3318    
TTR %, median [IQR] 68.5 [54.5-80.5] 69.0 [57.2-79.1] 0.473 
TTR>70%, n (%) 657 (47.3) 917 (47.5) 0.893 
TTR<65%, n (%) 600 (43.2) 776 (40.2) 0.087 
TTR<60%, n (%) 486 (35.0) 582 (30.2) 0.003 
TTR<50%, n (%) 257 (18.5) 289 (15.0) 0.007 
Legend: AF= atrial fibrillation; BMI= body mass index; CHA2DS2-VASc= congestive heart 
failure, hypertension, age≥75 years, diabetes mellitus, stroke/TIA, vascular disease, age 65-
74 years, sex category; CrCl= creatinine clearance; HAS-BLED= hypertension, abnormal renal 
and liver function, stroke, bleeding, labile INR, elderly, drugs or alcohol; IQR= interquartile 
range; TIA= transient ischemic attack; TTR= time in therapeutic range; VKA= vitamin K 
antagonist. 
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Table 2: Regression analysis for clinical predictors of time in therapeutic range according to 
geographic region 
 Beta 95% CI T p 
Europe     
Hypertension -3.084 -5.487 - -0.682 -2.519 0.012 
DBP at Baseline (per mmHg) 0.197 0.087-0.306 3.527 <0.001 
Prior VKA Use 7.484 5.226-9.743 6.500 <0.001 
North America     
Female Sex -2.861 -4.504 - -1.219 -3.417 0.001 
Persistent AF 3.656 1.451-5.861 3.252 0.001 
Diabetes Mellitus -2.189 -3.956 - -0.423 -2.431 0.015 
Chronic Heart Failure -2.352 -3.909 - -0.794 -2.961 0.003 
Prior VKA Use 6.187 4.086-8.289 5.773 <0.001 
Legend: AF= atrial fibrillation; CrCl= creatinine clearance; DBP= diastolic blood pressure; 
VKA= vitamin K antagonist.  
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Table 3: Cox multivariable regression analysis for study outcome in the overall population 
 HR 95% CI p 
i) Stroke/SEE 
Previous Stroke/TIA 1.91 1.18-3.09 0.009 
Coronary Artery Disease 1.78 1.13-2.81 0.013 
TTR (%) 0.98 0.97-0.99 0.001 
North America (vs. Europe) 0.55 0.35-0.86 0.008 
ii) Myocardial Infarction 
Previous Stroke/TIA 2.58 1.42-4.67 0.002 
Coronary Artery Disease 3.26 1.74-6.10 <0.001 
Concomitant Aspirin Use 0.27 0.10-0.76 0.013 
North America (vs. Europe) 2.34 1.19-4.59 0.014 
iii) Major Bleeding 
Age (per year) 1.05 1.02-1.07 <0.001 
Female Sex 0.65 0.42-0.98 0.041 
TTR (%) 0.98 0.97-0.98 <0.001 
North America (vs. Europe) 2.15 1.41-3.27 <0.001 
Legend: SEE= systemic embolic event; TIA= transient ischemic attack; TTR= time in 
therapeutic range. 
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FIGURE LEGENDS 
 
Figure 1: Distribution of time in therapeutic range according to geographic region 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 22 
DECLARATION OF CONFLICTING INTERESTS 
MP has been consultant for Boehringer Ingelheim. 
GYHL has been consultant for Bayer/Janssen, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, 
Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo.  Speaker for Bayer, 
BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. 
 
AUTHOR CONTRIBUTIONS 
MP and GYHL conceived the study, analysed and interpreted data, drafted and revised the 
manuscript. MP and GYHL have full access to data and take full responsibility for manuscript 
content. 
 
FUNDING 
No funding has been received in the preparation of this manuscript. Astra Zeneca provided 
datasets for the analysis. Astra Zeneca was never involved in any stage of manuscript 
drafting and preparation. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 23 
REFERENCES 
[1] D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, et al., 
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart 
Association, Circulation. 133 (2015) e38-360. doi:10.1161/CIR.0000000000000350. 
[2] E.J. Benjamin, D. Levy, S.M. Vaziri, R.B. D’Agostino, A.J. Belanger, P.A. Wolf, 
Independent risk factors for atrial fibrillation in a population-based cohort. The 
Framingham Heart Study., JAMA. 271 (1994) 840–4. 
http://www.ncbi.nlm.nih.gov/pubmed/8114238 (accessed February 23, 2016). 
[3] W.B. Kannel, R.D. Abbott, D.D. Savage, P.M. McNamara, Epidemiologic features of 
chronic atrial fibrillation: the Framingham study., N. Engl. J. Med. 306 (1982) 1018–
22. doi:10.1056/NEJM198204293061703. 
[4] P.A. Wolf, R.D. Abbott, W.B. Kannel, Atrial fibrillation: a major contributor to stroke in 
the elderly. The Framingham Study., Arch. Intern. Med. 147 (1987) 1561–4. 
http://www.ncbi.nlm.nih.gov/pubmed/3632164 (accessed May 23, 2016). 
[5] S.S. Chugh, R. Havmoeller, K. Narayanan, D. Singh, M. Rienstra, E.J. Benjamin, et al., 
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study., 
Circulation. 129 (2014) 837–47. doi:10.1161/CIRCULATIONAHA.113.005119. 
[6] F. Rahman, G.F. Kwan, E.J. Benjamin, Global epidemiology of atrial fibrillation., Nat. 
Rev. Cardiol. 11 (2014) 639–54. doi:10.1038/nrcardio.2014.118. 
[7] M. V Huisman, K.J. Rothman, M. Paquette, C. Teutsch, H.C. Diener, S.J. Dubner, et al., 
Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular 
Atrial Fibrillation: The GLORIA-AF Registry, Phase II., Am. J. Med. 128 (2015) 1306–
1313.e1. doi:10.1016/j.amjmed.2015.07.013. 
[8] J.L. Halperin, Ximelagatran compared with warfarin for prevention of 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 24 
thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, 
objectives, and design of a pair of clinical studies and baseline patient characteristics 
(SPORTIF III and V)., Am. Heart J. 146 (2003) 431–8. doi:10.1016/S0002-
8703(03)00325-9. 
[9] F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, E. Briët, A method to determine 
the optimal intensity of oral anticoagulant therapy., Thromb. Haemost. 69 (1993) 
236–9. http://www.ncbi.nlm.nih.gov/pubmed/8470047 (accessed April 8, 2015). 
[10] G.Y.H. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, H.J.G.M. Crijns, Refining clinical risk 
stratification for predicting stroke and thromboembolism in atrial fibrillation using a 
novel risk factor-based approach: the euro heart survey on atrial fibrillation., Chest. 
137 (2010) 263–72. doi:10.1378/chest.09-1584. 
[11] R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J.G.M. Crijns, G.Y.H. Lip, A novel 
user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with 
atrial fibrillation: the Euro Heart Survey., Chest. 138 (2010) 1093–100. 
doi:10.1378/chest.10-0134. 
[12] M. Proietti, D.A. Lane, G.Y.H. Lip, Chronic Kidney Disease, Time in Therapeutic Range 
and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial 
Fibrillation: Observations from the SPORTIF Trials, EBioMedicine. 8 (2016) 309–316. 
doi:10.1016/j.ebiom.2016.04.013. 
[13] C. Sarawate, M. V Sikirica, V.J. Willey, M.F. Bullano, O. Hauch, Monitoring 
anticoagulation in atrial fibrillation., J. Thromb. Thrombolysis. 21 (2006) 191–8. 
doi:10.1007/s11239-006-4968-z. 
[14] J. Menzin, L. Boulanger, O. Hauch, M. Friedman, C.B. Marple, G. Wygant, et al., 
Quality of anticoagulation control and costs of monitoring warfarin therapy among 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 25 
patients with atrial fibrillation in clinic settings: a multi-site managed-care study., 
Ann. Pharmacother. 39 (2005) 446–51. doi:10.1345/aph.1E169. 
[15] M.B. Nichol, T.K. Knight, T. Dow, G. Wygant, G. Borok, O. Hauch, et al., Quality of 
anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of 
anticoagulation clinic versus usual care., Ann. Pharmacother. 42 (2008) 62–70. 
doi:10.1345/aph.1K157. 
[16] D. McBride, B. Brüggenjürgen, S. Roll, S.N. Willich, Anticoagulation treatment for the 
reduction of stroke in atrial fibrillation: a cohort study to examine the gap between 
guidelines and routine medical practice., J. Thromb. Thrombolysis. 24 (2007) 65–72. 
doi:10.1007/s11239-006-0002-8. 
[17] C.J. Currie, P. McEwan, C. Emmas, C.L. Morgan, J.R. Peters, Anticoagulation in patients 
with non-valvular atrial fibrillation: an evaluation of stability and early factors that 
predict longer-term stability on warfarin in a large UK population., Curr. Med. Res. 
Opin. 21 (2005) 1905–13. doi:10.1185/030079905X75050. 
[18] J. Ansell, J. Hollowell, V. Pengo, F. Martinez-Brotons, J. Caro, L. Drouet, Descriptive 
analysis of the process and quality of oral anticoagulation management in real-life 
practice in patients with chronic non-valvular atrial fibrillation: the international study 
of anticoagulation management (ISAM)., J. Thromb. Thrombolysis. 23 (2007) 83–91. 
doi:10.1007/s11239-006-9022-7. 
[19] E.S. Mearns, C.M. White, C.G. Kohn, J. Hawthorne, J.-S. Song, J. Meng, et al., Quality 
of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-
analysis and meta-regression., Thromb. J. 12 (2014) 14. doi:10.1186/1477-9560-12-
14. 
[20] D.E. Singer, A.S. Hellkamp, J.P. Piccini, K.W. Mahaffey, Y. Lokhnygina, G. Pan, et al., 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 26 
Impact of global geographic region on time in therapeutic range on warfarin 
anticoagulant therapy: data from the ROCKET AF clinical trial., J. Am. Heart Assoc. 2 
(2013) e000067. doi:10.1161/JAHA.112.000067. 
[21] S.D. Pokorney, D.N. Simon, L. Thomas, G.C. Fonarow, P.R. Kowey, P. Chang, et al., 
Patients’ time in therapeutic range on warfarin among US patients with atrial 
fibrillation: Results from ORBIT-AF registry, Am. Heart J. 170 (2015) 141–148.e1. 
doi:10.1016/j.ahj.2015.03.017. 
[22] S. Apostolakis, R.M. Sullivan, B. Olshansky, G.Y.H. Lip, Factors affecting quality of 
anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-
TT₂R₂ score., Chest. 144 (2013) 1555–63. doi:10.1378/chest.13-0054. 
[23] M. Proietti, G.Y.H. Lip, Simple decision-making between a vitamin K antagonist and a 
non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score, Eur. Hear. 
J. - Cardiovasc. Pharmacother. 1 (2015) 150–152. doi:10.1093/ehjcvp/pvv012. 
[24] Y. Wan, C. Heneghan, R. Perera, N. Roberts, J. Hollowell, P. Glasziou, et al., 
Anticoagulation control and prediction of adverse events in patients with atrial 
fibrillation: a systematic review., Circ. Cardiovasc. Qual. Outcomes. 1 (2008) 84–91. 
doi:10.1161/CIRCOUTCOMES.108.796185. 
[25] P. Gallego, V. Roldan, F. Marín, M. Romera, M. Valdés, V. Vicente, et al., Cessation of 
oral anticoagulation in relation to mortality and the risk of thrombotic events in 
patients with atrial fibrillation, Thromb. Haemost. 110 (2013) 1189–1198. 
doi:10.1160/TH13-07-0556. 
[26] V. Sjögren, B. Grzymala-Lubanski, H. Renlund, L. Friberg, G.Y.H. Lip, P.J. Svensson, et 
al., Safety and efficacy of well managed warfarin. A report from the Swedish quality 
register Auricula., Thromb. Haemost. 113 (2015) 1370–7. doi:10.1160/TH14-10-0859. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 27 
[27] A.M. Gallagher, E. Setakis, J.M. Plumb, A. Clemens, T.-P. van Staa, Risks of stroke and 
mortality associated with suboptimal anticoagulation in atrial fibrillation patients., 
Thromb. Haemost. 106 (2011) 968–77. doi:10.1160/TH11-05-0353. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 28 
 
Figure 1 
